Multiple Myeloma News


Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Farydak (panobinostat), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), melflufen, MOR202, oprozomib, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Jun 26, 2015 3:03 pm | One Comment ]
Farydak Gets Positive Opinion From European Advisory Committee; Approval Expected Within Three Months

An advisory committee of the European Medicines Agency has issued a positive opinion regarding European approval of Farydak (panobinostat) for the treat­ment of cer­tain patients with multiple myeloma.

Specifically, the Committee for Medicinal Products for Human Use (CHMP) rec­om­mended that Farydak be approved for use in com­bi­na­tion with Velcade (bor­tez­omib) and dexa­meth­a­sone (Decadron) for the treatment of re­lapsed and/​or refractory multiple myeloma patients who have received at least two prior treatment regimens.

The two prior regimens must include Velcade and at least one treatment from the immunomodulatory class …

Read the full story »
[ by | Jun 25, 2015 3:02 pm | 4 Comments ]
Multiple Myeloma Highlights From The 2015 ASCO, EHA, And IMWG Annual Summit Meetings

The annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral presentations, posters, and e-abstracts summarizing the results of new oncology- and hematology-related research.

Included in the research presented at the two meetings were more than 200 studies discussing new multiple myeloma-related findings.

In addition to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Working …

Read the full story »
[ by | Jun 7, 2015 1:15 pm | No Comment ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Potential New Myeloma Therapies

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a number of poster presentations related to multiple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, research results are made available for review by meeting attendees in the form of posters, each of which summarizes the results of a single study. Each poster is typically about two feet high by three or four feet in length, and all posters during a ses­sion are displayed throughout a large conference hall.

Most of …

Read the full story »
[ by | Jun 5, 2015 6:14 pm | One Comment ]
Daratumumab FDA Application And Review Process Starts

The potential new myeloma therapy daratumumab just got a little closer to being available to U.S. multiple myeloma patients outside of clinical trials.

Johnson and Johnson (NYSE:JNJ) announced today that its Janssen subsidiary has started the process of applying to the U.S. Food and Drug Administration (FDA) to have daratumumab approved as a new treatment for relapsed multiple myeloma.

In particular, Johnson and Johnson has started a rolling submission of a biologics license application to the FDA for daratumumab.

A rolling submission allows Johnson and Jonson to submit completed …

Read the full story »
[ by | Updated: Jun 4, 2015 6:25 pm | 8 Comments ]
CAR T-Cell Therapy For Multiple Myeloma: Promising Signs Of Efficacy (ASCO 2015)

There was an important multiple myeloma-related presentation this Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

The presentation summarized early results of a pilot clinical trial being conducted at the University of Pennsylvania. The trial, which is scheduled to enroll 10 re­lapsed myeloma patients, is testing a promising approach to cancer treatment known as “chimeric antigen receptor” (CAR) T-cell therapy.

CAR T-cell therapy has generated impressive results when used to treat certain kinds of leukemia and lymphoma. These results have led to a concerted effort …

Read the full story »
[ by | Jun 1, 2015 7:55 pm | 7 Comments ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Current Therapies; Impact Of Del(17p) And T(11;14)

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.

During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.

Most …

Read the full story »